Selected research
Market Analysis & Forecast
Global Coagulation Factor XI Market Analysis and Forecast 2026-2032
Market perspective
The global Coagulation Factor XI market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for Coagulation Factor XI is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for Coagulation Factor XI is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Read the full market overview
Asia-Pacific market for Coagulation Factor XI is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The China market for Coagulation Factor XI is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The major global companies of Coagulation Factor XI include Bristol-Myers Squibb Company, Cambryn Biologics LLC, eXithera Pharmaceuticals, Inc, Ionis Pharmaceuticals, Inc., LegoChem Biosciences, Inc and Bayer AG, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Coagulation Factor XI, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of Coagulation Factor XI, also provides the revenue of main regions and countries. Of the upcoming market potential for Coagulation Factor XI, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Coagulation Factor XI revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Coagulation Factor XI market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Coagulation Factor XI revenue, projected growth trends, production technology, application and end-user industry.
Coagulation Factor XI Segment by Company
Bristol-Myers Squibb Company
Cambryn Biologics LLC
eXithera Pharmaceuticals, Inc
Ionis Pharmaceuticals, Inc.
LegoChem Biosciences, Inc
Bayer AG
Coagulation Factor XI Segment by Type
MR-1007
IONIS-FXIRx
EP-7041
BMS-262084
AB-022
Others
Coagulation Factor XI Segment by Application
Thrombosis
Acute Ischemic Stroke
Bleeding and Clotting Disorders
Others
Coagulation Factor XI Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Coagulation Factor XI market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Coagulation Factor XI and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Coagulation Factor XI.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Coagulation Factor XI in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Coagulation Factor XI company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Coagulation Factor XI revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- MR-1007
- IONIS-FXIRx
- EP-7041
- BMS-262084
- AB-022
- Others
Applications
- Thrombosis
- Acute Ischemic Stroke
- Bleeding and Clotting Disorders
- Others
Companies covered
- Bristol-Myers Squibb Company
- Cambryn Biologics LLC
- eXithera Pharmaceuticals, Inc
- Ionis Pharmaceuticals, Inc.
- LegoChem Biosciences, Inc
- Bayer AG
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Coagulation Factor XI Market by Type
- 1.2.1 Global Coagulation Factor XI Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 MR-1007
- 1.2.3 IONIS-FXIRx
- 1.2.4 EP-7041
- 1.2.5 BMS-262084
- 1.2.6 AB-022
- 1.2.7 Others
- 1.3 Coagulation Factor XI Market by Application
- 1.3.1 Global Coagulation Factor XI Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 Thrombosis
- 1.3.3 Acute Ischemic Stroke
- 1.3.4 Bleeding and Clotting Disorders
- 1.3.5 Others
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Coagulation Factor XI Market Dynamics
- 2.1 Coagulation Factor XI Industry Trends
- 2.2 Coagulation Factor XI Industry Drivers
- 2.3 Coagulation Factor XI Industry Opportunities and Challenges
- 2.4 Coagulation Factor XI Industry Restraints
3 Global Growth Perspective
- 3.1 Global Coagulation Factor XI Market Perspective (2021-2032)
- 3.2 Global Coagulation Factor XI Growth Trends by Region
- 3.2.1 Global Coagulation Factor XI Market Size by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global Coagulation Factor XI Market Size by Region (2021-2026)
- 3.2.3 Global Coagulation Factor XI Market Size by Region (2027-2032)
4 Competitive Landscape by Players
- 4.1 Global Coagulation Factor XI Revenue by Players
- 4.1.1 Global Coagulation Factor XI Revenue by Players (2021-2026)
- 4.1.2 Global Coagulation Factor XI Revenue Market Share by Players (2021-2026)
- 4.1.3 Global Coagulation Factor XI Players Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global Coagulation Factor XI Key Players Ranking, 2024 VS 2025 VS 2026
- 4.3 Global Coagulation Factor XI Key Players Headquarters & Area Served
- 4.4 Global Coagulation Factor XI Players, Product Type & Application
- 4.5 Global Coagulation Factor XI Players Establishment Date
- 4.6 Market Competitive Analysis
- 4.6.1 Global Coagulation Factor XI Market CR5 and HHI
- 4.6.3 2025 Coagulation Factor XI Tier 1, Tier 2, and Tier 3
5 Coagulation Factor XI Market Size by Type
- 5.1 Global Coagulation Factor XI Revenue by Type (2021 VS 2025 VS 2032)
- 5.2 Global Coagulation Factor XI Revenue by Type (2021-2032)
- 5.3 Global Coagulation Factor XI Revenue Market Share by Type (2021-2032)
6 Coagulation Factor XI Market Size by Application
- 6.1 Global Coagulation Factor XI Revenue by Application (2021 VS 2025 VS 2032)
- 6.2 Global Coagulation Factor XI Revenue by Application (2021-2032)
- 6.3 Global Coagulation Factor XI Revenue Market Share by Application (2021-2032)
7 Company Profiles
- 7.1 Bristol-Myers Squibb Company
- 7.1.1 Bristol-Myers Squibb Company Company Information
- 7.1.2 Bristol-Myers Squibb Company Business Overview
- 7.1.3 Bristol-Myers Squibb Company Coagulation Factor XI Revenue and Gross Margin (2021-2026)
- 7.1.4 Bristol-Myers Squibb Company Coagulation Factor XI Product Portfolio
- 7.1.5 Bristol-Myers Squibb Company Recent Developments
- 7.2 Cambryn Biologics LLC
- 7.2.1 Cambryn Biologics LLC Company Information
- 7.2.2 Cambryn Biologics LLC Business Overview
- 7.2.3 Cambryn Biologics LLC Coagulation Factor XI Revenue and Gross Margin (2021-2026)
- 7.2.4 Cambryn Biologics LLC Coagulation Factor XI Product Portfolio
- 7.2.5 Cambryn Biologics LLC Recent Developments
- 7.3 eXithera Pharmaceuticals, Inc
- 7.3.1 eXithera Pharmaceuticals, Inc Company Information
- 7.3.2 eXithera Pharmaceuticals, Inc Business Overview
- 7.3.3 eXithera Pharmaceuticals, Inc Coagulation Factor XI Revenue and Gross Margin (2021-2026)
- 7.3.4 eXithera Pharmaceuticals, Inc Coagulation Factor XI Product Portfolio
- 7.3.5 eXithera Pharmaceuticals, Inc Recent Developments
- 7.4 Ionis Pharmaceuticals, Inc.
- 7.4.1 Ionis Pharmaceuticals, Inc. Company Information
- 7.4.2 Ionis Pharmaceuticals, Inc. Business Overview
- 7.4.3 Ionis Pharmaceuticals, Inc. Coagulation Factor XI Revenue and Gross Margin (2021-2026)
- 7.4.4 Ionis Pharmaceuticals, Inc. Coagulation Factor XI Product Portfolio
- 7.4.5 Ionis Pharmaceuticals, Inc. Recent Developments
- 7.5 LegoChem Biosciences, Inc
- 7.5.1 LegoChem Biosciences, Inc Company Information
- 7.5.2 LegoChem Biosciences, Inc Business Overview
- 7.5.3 LegoChem Biosciences, Inc Coagulation Factor XI Revenue and Gross Margin (2021-2026)
- 7.5.4 LegoChem Biosciences, Inc Coagulation Factor XI Product Portfolio
- 7.5.5 LegoChem Biosciences, Inc Recent Developments
- 7.6 Bayer AG
- 7.6.1 Bayer AG Company Information
- 7.6.2 Bayer AG Business Overview
- 7.6.3 Bayer AG Coagulation Factor XI Revenue and Gross Margin (2021-2026)
- 7.6.4 Bayer AG Coagulation Factor XI Product Portfolio
- 7.6.5 Bayer AG Recent Developments
8 North America
- 8.1 North America Coagulation Factor XI Revenue (2021-2032)
- 8.2 North America Coagulation Factor XI Revenue by Type (2021-2032)
- 8.2.1 North America Coagulation Factor XI Revenue by Type (2021-2026)
- 8.2.2 North America Coagulation Factor XI Revenue by Type (2027-2032)
- 8.3 North America Coagulation Factor XI Revenue Share by Type (2021-2032)
- 8.4 North America Coagulation Factor XI Revenue by Application (2021-2032)
- 8.4.1 North America Coagulation Factor XI Revenue by Application (2021-2026)
- 8.4.2 North America Coagulation Factor XI Revenue by Application (2027-2032)
- 8.5 North America Coagulation Factor XI Revenue Share by Application (2021-2032)
- 8.6 North America Coagulation Factor XI Revenue by Country
- 8.6.1 North America Coagulation Factor XI Revenue by Country (2021 VS 2025 VS 2032)
- 8.6.2 North America Coagulation Factor XI Revenue by Country (2021-2026)
- 8.6.3 North America Coagulation Factor XI Revenue by Country (2027-2032)
- 8.6.4 United States
- 8.6.5 Canada
9 Europe
- 9.1 Europe Coagulation Factor XI Revenue (2021-2032)
- 9.2 Europe Coagulation Factor XI Revenue by Type (2021-2032)
- 9.2.1 Europe Coagulation Factor XI Revenue by Type (2021-2026)
- 9.2.2 Europe Coagulation Factor XI Revenue by Type (2027-2032)
- 9.3 Europe Coagulation Factor XI Revenue Share by Type (2021-2032)
- 9.4 Europe Coagulation Factor XI Revenue by Application (2021-2032)
- 9.4.1 Europe Coagulation Factor XI Revenue by Application (2021-2026)
- 9.4.2 Europe Coagulation Factor XI Revenue by Application (2027-2032)
- 9.5 Europe Coagulation Factor XI Revenue Share by Application (2021-2032)
- 9.6 Europe Coagulation Factor XI Revenue by Country
- 9.6.1 Europe Coagulation Factor XI Revenue by Country (2021 VS 2025 VS 2032)
- 9.6.2 Europe Coagulation Factor XI Revenue by Country (2021-2026)
- 9.6.3 Europe Coagulation Factor XI Revenue by Country (2027-2032)
- 9.6.4 Germany
- 9.6.5 France
- 9.6.6 U.K.
- 9.6.7 Italy
- 9.6.8 Netherlands
10 China
- 10.1 China Coagulation Factor XI Revenue (2021-2032)
- 10.2 China Coagulation Factor XI Revenue by Type (2021-2032)
- 10.2.1 China Coagulation Factor XI Revenue by Type (2021-2026)
- 10.2.2 China Coagulation Factor XI Revenue by Type (2027-2032)
- 10.3 China Coagulation Factor XI Revenue Share by Type (2021-2032)
- 10.4 China Coagulation Factor XI Revenue by Application (2021-2032)
- 10.4.1 China Coagulation Factor XI Revenue by Application (2021-2026)
- 10.4.2 China Coagulation Factor XI Revenue by Application (2027-2032)
- 10.5 China Coagulation Factor XI Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia Coagulation Factor XI Revenue (2021-2032)
- 11.2 Asia Coagulation Factor XI Revenue by Type (2021-2032)
- 11.2.1 Asia Coagulation Factor XI Revenue by Type (2021-2026)
- 11.2.2 Asia Coagulation Factor XI Revenue by Type (2027-2032)
- 11.3 Asia Coagulation Factor XI Revenue Share by Type (2021-2032)
- 11.4 Asia Coagulation Factor XI Revenue by Application (2021-2032)
- 11.4.1 Asia Coagulation Factor XI Revenue by Application (2021-2026)
- 11.4.2 Asia Coagulation Factor XI Revenue by Application (2027-2032)
- 11.5 Asia Coagulation Factor XI Revenue Share by Application (2021-2032)
- 11.6 Asia Coagulation Factor XI Revenue by Country
- 11.6.1 Asia Coagulation Factor XI Revenue by Country (2021 VS 2025 VS 2032)
- 11.6.2 Asia Coagulation Factor XI Revenue by Country (2021-2026)
- 11.6.3 Asia Coagulation Factor XI Revenue by Country (2027-2032)
- 11.6.4 Japan
- 11.6.5 South Korea
- 11.6.6 India
- 11.6.7 Australia
- 11.6.8 Taiwan
- 11.6.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA Coagulation Factor XI Revenue (2021-2032)
- 12.2 SAMEA Coagulation Factor XI Revenue by Type (2021-2032)
- 12.2.1 SAMEA Coagulation Factor XI Revenue by Type (2021-2026)
- 12.2.2 SAMEA Coagulation Factor XI Revenue by Type (2027-2032)
- 12.3 SAMEA Coagulation Factor XI Revenue Share by Type (2021-2032)
- 12.4 SAMEA Coagulation Factor XI Revenue by Application (2021-2032)
- 12.4.1 SAMEA Coagulation Factor XI Revenue by Application (2021-2026)
- 12.4.2 SAMEA Coagulation Factor XI Revenue by Application (2027-2032)
- 12.5 SAMEA Coagulation Factor XI Revenue Share by Application (2021-2032)
- 12.6 SAMEA Coagulation Factor XI Revenue by Country
- 12.6.1 SAMEA Coagulation Factor XI Revenue by Country (2021 VS 2025 VS 2032)
- 12.6.2 SAMEA Coagulation Factor XI Revenue by Country (2021-2026)
- 12.6.3 SAMEA Coagulation Factor XI Revenue by Country (2027-2032)
- 12.6.4 Brazil
- 12.6.5 Argentina
- 12.6.6 Chile
- 12.6.7 Colombia
- 12.6.8 Peru
- 12.6.9 Saudi Arabia
- 12.6.10 Israel
- 12.6.11 UAE
- 12.6.12 Turkey
- 12.6.13 Iran
- 12.6.14 Egypt
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst